Photo from wikipedia
It is imperative to explore potential biomarkers for predicting clinical outcome and developing targeted therapies for T‐cell acute lymphoblastic leukemia (T‐ALL). This study aimed to investigate the mutation patterns of… Click to show full abstract
It is imperative to explore potential biomarkers for predicting clinical outcome and developing targeted therapies for T‐cell acute lymphoblastic leukemia (T‐ALL). This study aimed to investigate the mutation patterns of tumor necrosis factor‐alpha‐inducing protein 3 (TNFAIP3, also known as A20) and its role in the prognosis of T‐ALL patients.
Keywords:
factor;
lymphoblastic leukemia;
acute lymphoblastic;
cell acute;
mutation
Journal Title: Cancer Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!